

VHL(Phospho Ser68) Polyclonal Antibody

Description

Product type	Primary Antibody
Code	BT-AP15470
Host	Rabbit
Isotype	IgG
Size	100ul, 50ul, 20ul
Immunogen	The antiserum was produced against synthesized peptide derived from human VHL around the phosphorylation site of Ser68. AA range:34-83
Mol wt	24153
Species reactivity	Human, Mouse, Rat
Clonality	Polyclonal
Recommended application	IHC-p, IF, ELISA
Concentration	1 mg/ml
Full name	Von Hippel-Lindau disease tumor suppressor
Synonyms	Von Hippel-Lindau disease tumor suppressor; VHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.

Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Recommended Dilution

WB: 1: 500 - 1: 2000

IHC-p: 1: 100 - 1: 300

ELISA: 1: 5000

Not yet tested in other applications.

Images

No images.

Storage

-20°C for 1 year